HCC-44 Xenograft Model Service for NSCLC

The HCC-44 Xenograft Model Service for NSCLC provides a robust preclinical platform for evaluating therapeutic efficacy against lung adenocarcinoma, leveraging the well-characterized HCC-44 cell line harboring key oncogenic driver mutations. Alfa Cytology delivers comprehensive HCC-44 xenograft model construction and endpoint analysis services, enabling researchers to advance NSCLC drug discovery programs with reliable, reproducible preclinical data.

Overview of HCC-44 Xenograft Model for NSCLC

The HCC-44 xenograft model is a widely utilized preclinical system for studying non-small cell lung cancer (NSCLC), specifically lung adenocarcinoma. Derived from the HCC-44 cell line, which was established from a 54-year-old female patient with lung adenocarcinoma, this model exhibits key molecular features relevant to NSCLC biology, including a homozygous KRAS G12C mutation (c.34G>T) and homozygous TP53 mutations (p.Ser94Ter and p.Arg175Leu). The HCC-44 cell line demonstrates an epithelial morphology with adherent growth characteristics and a doubling time of approximately 29–37 hours, making it suitable for robust tumor engraftment and growth monitoring in immunocompromised hosts. The model has been extensively applied in studies evaluating chemotherapy sensitivity, immune checkpoint inhibitor combinations, and radiation response, providing valuable insights into treatment efficacy and resistance mechanisms in KRAS-mutant NSCLC.

Fig 1. p38 activation underlies USP16 deficiency-mediated inhibition of tumor growth. (Xu, Guiqin, et al., 2021)

As a cell line-derived xenograft (CDX) model, HCC-44 offers several advantages for preclinical research, including consistent tumor growth kinetics, well-defined genetic background, and compatibility with standard pharmacological and immunological endpoints. The model supports both subcutaneous and orthotopic implantation strategies, allowing researchers to study tumor progression, metastatic potential, and drug distribution in relevant tissue microenvironments. Given the prevalence of KRAS mutations in approximately 25–30% of NSCLC cases, the HCC-44 xenograft model serves as a critical tool for developing targeted therapies against this historically challenging oncogenic driver.

Cell Line Information: HCC-44

The HCC-44 cell line is a well-characterized human non-small cell lung cancer (NSCLC) model derived from lung adenocarcinoma tissue. Below is a comprehensive summary of its key characteristics:

Our Services

Alfa Cytology specializes in the development and characterization of HCC-44 xenograft models for NSCLC preclinical research, offering end-to-end services from cell line authentication and quality control to tumor implantation, in-life monitoring, and comprehensive endpoint analysis. Our experienced team ensures rigorous experimental design, consistent tumor take rates, and reproducible pharmacological data to support your therapeutic development pipeline. Whether you require standard subcutaneous models or customized orthotopic implantation strategies, Alfa Cytology provides the technical expertise and infrastructure to accelerate your NSCLC drug discovery programs.

Workflow of HCC-44 Xenograft Model Construction

The construction of the HCC-44 xenograft model follows a standardized yet flexible workflow designed to ensure tumor engraftment consistency, animal welfare compliance, and high-quality data generation. The process begins with authenticated HCC-44 cell culture and progresses through implantation, monitoring, and endpoint analysis phases.

1. Cell Line Authentication and Quality Control: HCC-44 cells are authenticated via STR profiling and confirmed negative for mycoplasma contamination prior to implantation. Cells are maintained in RPMI 1640 supplemented with 10% FBS under standard culture conditions (37°C, 5% CO₂) to ensure optimal viability and growth kinetics.
2. Cell Harvest and Preparation: Exponentially growing HCC-44 cells are harvested using standard trypsinization protocols, washed with PBS, and resuspended in a suitable carrier matrix (e.g., Matrigel or PBS) at the desired concentration. Cell viability is confirmed by trypan blue exclusion, typically requiring >95% viability for reliable engraftment.
3. Animal Selection and Preparation: Immunocompromised mouse strains (e.g., Nude, NOD-SCID, or NSG) are selected based on study objectives and housed under specific pathogen-free (SPF) conditions. Animals are acclimatized for a minimum of one week prior to implantation, with baseline body weights and health status recorded.
4. Tumor Implantation: HCC-44 cells are implanted either subcutaneously (typically into the flank region) or orthotopically (into the lung parenchyma) depending on the research question. Subcutaneous implantation generally employs 1×10⁶ to 5×10⁶ cells per site, while orthotopic models require specialized surgical techniques and lower cell numbers.
5. Tumor Monitoring and Measurement: Tumor growth is monitored by caliper measurement (length × width) twice weekly, with tumor volume calculated using the modified ellipsoid formula (V = 0.5 × L × W²). Body weights and general health observations are recorded concurrently to assess treatment-related toxicity.
6. Treatment Administration: Once tumors reach the predetermined volume (typically 100–200 mm³), animals are randomized into treatment groups. Test compounds, vehicle controls, or reference standards are administered according to the study protocol, with dosing schedules tailored to the pharmacological properties of each agent.
7. Endpoint Analysis and Data Collection: At study termination, tumors are excised, weighed, and processed for downstream analyses including histopathology (H&E, IHC), molecular profiling (Western blot, qPCR), and pharmacokinetic studies. Blood samples may be collected for hematology and clinical chemistry assessments.
8. Data Compilation and Reporting: All experimental data, including tumor growth curves, body weight changes, survival data, and histological findings, are compiled into a comprehensive study report with statistical analysis. Data are presented in a format suitable for regulatory submission or publication.

Fig 2. HCC-44 xenograft model construction workflow.

Case Study-HCC-44 Xenograft Model Development

In a representative preclinical study, the HCC-44 xenograft model was employed to evaluate the antitumor efficacy of a novel therapeutic candidate in KRAS-mutant NSCLC. Following subcutaneous implantation of HCC-44 cells into immunocompromised mice, tumors were allowed to establish and reach a palpable size before randomization into treatment cohorts. The test compound was administered according to a predefined dosing regimen, with tumor growth, body weight, and overall animal health monitored throughout the study duration. Endpoint analysis revealed measurable differences in tumor burden between treatment and control groups, with histological examination confirming changes in tumor cell proliferation and apoptosis markers. These preclinical findings provided supportive data for the therapeutic candidate's mechanism of action and informed subsequent development decisions. Additional studies may explore combination strategies with standard-of-care agents, dose-response relationships, and biomarker correlates of response to further characterize the compound's preclinical profile.

Why Choose Alfa Cytology?

Alfa Cytology offers a differentiated approach to HCC-44 xenograft model services, combining scientific rigor with operational flexibility to meet diverse preclinical research needs. Our key advantages include:

• Authenticated HCC-44 cell lines with verified STR profiles and mycoplasma-free certification, ensuring model fidelity and reproducibility.
• Flexible implantation options including subcutaneous and orthotopic models, tailored to your specific research objectives and pharmacological questions.
• Comprehensive in-life monitoring with twice-weekly tumor measurements, body weight tracking, and detailed health observations to ensure data integrity.
• Robust endpoint analysis capabilities spanning histopathology, immunohistochemistry, molecular profiling, and pharmacokinetic assessments.
• Experienced study design consultation to optimize dosing schedules, group sizes, and statistical power for your preclinical program.
• Rapid project turnaround with dedicated project management and transparent communication throughout the study lifecycle.
• Compliance with animal welfare standards and regulatory guidelines, ensuring ethical conduct and audit-ready documentation.

Contact Us

Ready to advance your NSCLC therapeutic program with the HCC-44 xenograft model? Contact us today to discuss your project requirements, timelines, and custom study designs. Our team is prepared to provide detailed proposals and scientific consultation to support your preclinical research objectives. Reach out to us and let Alfa Cytology be your trusted partner in accelerating drug discovery against KRAS-mutant lung cancer.

For research use only. Not intended for any clinical use.